Focus: Acrotech Biopharma is a public specialty pharmaceutical company headquartered in East Windsor, NJ, focused on oncology and hematology with a portfolio of marketed therapies and early-stage pipeline programs. The company operates as a specialty pharma player with a concentrated portfolio in cancer indications.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Acrotech Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship myeloma therapy with 10-year exclusivity runway; represents core franchise strength in hematologic malignancy.
Help build intelligence for Acrotech Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Acrotech Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Liposomal formulation innovation; long-standing lymphoma standard with no disclosed LOE date.
Adjunct to fluorouracil/methotrexate therapy; longest LOE horizon among portfolio but supporting role in combination regimens.
Niche orphan oncology product; transitioning to generic with Phase 3 pipeline study ongoing, indicating life-cycle management effort.
Histone deacetylase inhibitor facing imminent patent cliff; supported by Phase 3 trial continuation but limited differentiation.
Older franchise with approaching exclusivity loss and minimal pipeline support beyond Phase 1 studies.
Recently launched PDE-4 inhibitor targeting dermatology—represents strategic diversification outside oncology with Phase 3 development backing.
Historic alkylating agent approaching generic conversion; significant myeloma/lymphoma heritage but limited differentiation in modern landscape.
4 discontinued, 0 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
+2 more
+2 more